Oct 23

Competitor Offers Equivalent To Turing’s Scandalous $750 Pill For Just $1:

Having become an overnight social and industry outcast, at least Turing Pharma’s Martin Shkreli had one thing going for him: a business model that afforded him solid margins, because despite promising to cut the price of the scandalous Daraprim, Turing did not do that. Now, however, even that may be in jeopardy following news that San Diego-based specialty drug maker Imprimis Pharmaceuticals, says it can make a close, customized version of Daraprim for a paltry $1 a pill, NBC reports. That’s a big contrast to the $750-a-dose that Shkreli said Turing was going to start charging for the same drug.

Tags: , , ,

Leave a Reply